Introduction
Peripheral artery disease (PAD) is a common and debilitating vascular complication among individuals with type 2 diabetes, characterized by atherosclerosis that impairs lower extremity perfusion, leading to reduced functional capacity, increased risk of limb events, and diminished quality of life. Despite its high prevalence and impact, therapeutic options targeting functional impairment in symptomatic PAD remain limited, particularly therapies that address metabolic comorbidities such as diabetes and obesity. The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial was designed to assess the effects of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), on walking function and symptom burden in this population.
